Literature DB >> 16644740

Chaperoning drug development with PET.

Wolfgang A Weber1.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16644740

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  4 in total

1.  Optimisation and harmonisation: two sides of the same coin?

Authors:  Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-15       Impact factor: 9.236

Review 2.  Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis.

Authors:  Kelly E Henry; Gary A Ulaner; Jason S Lewis
Journal:  PET Clin       Date:  2017-07

3.  FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer.

Authors:  Jae Sung Lee; Hajime Orita; Kathleen Gabrielson; Sara Alvey; Ruth L Hagemann; Francis P Kuhajda; Edward Gabrielson; Martin G Pomper
Journal:  Pharm Res       Date:  2007-04-03       Impact factor: 4.580

4.  Variation in urinary excretion of FDG, yet another uncertainty in quantitative PET.

Authors:  Tore Bach-Gansmo; Ja Dybvik; Tc Adamsen; A Naum
Journal:  Acta Radiol Short Rep       Date:  2012-09-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.